N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system

A compound according to formula I,

• wherein:
• A is selected from phenyl and heteroaryl;
• B is selected from phenyl and heteroaryl;
• L is a linker selected from alkylene and O;
• R1 is selected from H, alkyl, alkoxy, S-alkyl, S(O)qalkyl, COR5, CONR5R6, COOR5, CH2OH, OH, F and Cl;
• R2 is selected from NR7R8, CR11R12NR7R8, CONR7R8, (CR11R12)2NR7R8 and (CR11R12)3NR7R8, wherein R1 is alkyl, alkoxy, CH2OH, COR5, CONR5R6 or COOR5 when R2 is NR7R8;
• R3 is selected from H, alkyl, alkoxy, NR7R8, CH2OH, OH, F and Cl;
• or R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, wherein the heterocyclyl or heteroaryl contains at least one ring member selected from N and NR13;
• provided that when R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, L is O;
• provided that when R1 is H, either
• R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl;
• or
• R3 is selected from alkyl, alkoxy, NR7R8, CH2OH, OH, F and Cl;
• R4, R5 and R6 are each independently selected from H and alkyl;
• R7 and R8 are independently selected from H, alkyl, cycloalkyl, heterocyclyl, and C(O)R10, wherein when R7 is C(O)R10, R8 is H or alkyl;
• or R7 and R8 may come together with the nitrogen atom to which they are attached to form heterocyclyl;
• R9a, R9b, R9c, R9d, R9e and R9f are independently selected from H and alkyl;
• R10 is selected from alkyl, aryl, heterocyclyl and heteroaryl;
• is absent or represents a bond, wherein when is a bond R1 and R4 are absent;
• m is 0, 1 or 2, wherein when m is 2, n is 0;
• n is 0, 1 or 2, wherein when n is 2, m is 0;
• q is 1 or 2;
• alkyl is a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6);
• alkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents selected from S-alkyl, S(O)alkyl, S(O)2alkyl, cycloalkyl, heterocyclyl, alkoxy, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14;
• cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms (C3-C7);
• cycloalkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, alkoxy, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, and NR13R14;
• phenyl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
• alkylene is a bivalent C1-3 straight-chained alkyl radical or a bivalent C3-4 branched alkyl radical, wherein alkylene may optionally be substituted with 1 or 2 substituents selected from S-alkyl, S(O)alkyl, S(O)2alkyl, heterocyclyl, alkoxy, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14;
• heterocyclyl is a monocyclic ring which is saturated or partially unsaturated, containing, where possible, 1 or 2 ring members independently selected from N, S, O and NR13 and 2 to 5 carbon atoms;
• heterocyclyl may optionally be substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, oxo, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
• heteroaryl is a 5 or 6 membered aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR13, S and O;
• heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
• alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6);
• alkoxy may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR4 and NR13R14;
• R11, R12, R13 and R14 are independently selected from H and alkyl;
• and tautomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof;
• wherein the compound of formula I is not: